CRISPR/Cas9-Mediated Targeting of the Integrin Beta-2 Gene as a Gene-Editing Strategy for Leukocyte Adhesion Deficiency Type I.
- 1Department of Stem Cells Technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran, Iran.
- 2Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- 3Pediatric Cell and Gene Therapy Research Center, Gene, Cell, and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
Leukocyte adhesion deficiency (LAD) is a genetic immunodeficiency that severely impairs the leukocyte adhesion cascade and migration to the sites of infection and inflammation. As a result, the main consequence is recurrent and severe infections with bacteria and fungi, which can lead to death. The most common variant, LAD-I, is due to mutations in the integrin beta 2 (ITGB2) gene responsible for the β2 integrin (CD18) subunit. Corrective strategies based on gene therapy and genome editing are the most promising methods for treating genetic defects. In the present experimental in vitro study conducted at Tarbiat Modares University, Tehran, Iran, in 2024, we designed a single-guide RNA (sgRNA) for the CRISPR/Cas9 system to target exon 6 of ITGB2 and performed validation experiments. We also investigated peptide nanocarriers as a potential strategy for delivering the CRISPR components. The PX458 plasmid encoding Cas9 and the designed sgRNA was delivered into HEK293T cells, followed by genome-editing analysis. Genome-editing analysis confirmed a measurable level of indel formation at the target locus. Furthermore, the results of MPG nanopeptide production and purification demonstrate the potential of peptide nanocarriers for genome-editing systems. Overall, this work establishes a foundation for subsequent knock-in and gene-correction studies in clinically relevant immune cell models, paving the way for potential LAD-I gene therapy applications.
Related
- Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease
- Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.
- Computational modelling of acetylcholine deficiency-mediated dysfunction in the basal ganglia-thalamocortical network related to Parkinson’s disease dementia
- Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency
- NEURL1-mediated K63-ubiquitination of SLC40A1 drives ferroptosis resistance in pathological scars: Therapeutic targeting via autophagy-activating microneedles.
BibTeX
@article{raji2026crisprcas9mediated,
title = {{CRISPR/Cas9-Mediated Targeting of the Integrin Beta-2 Gene as a Gene-Editing Strategy for Leukocyte Adhesion Deficiency Type I.}},
author = {Sevil Raji and Hossein Soltaninejad and Saman Hosseinkhani and Amir Ali Hamidieh},
journal = {Iranian journal of medical sciences},
year = {2026},
month = oct,
doi = {10.30476/ijms.2026.109631.4499},
url = {https://europepmc.org/article/MED/42999773},
note = {CC BY-ND},
}
RIS
TY - JOUR
TI - CRISPR/Cas9-Mediated Targeting of the Integrin Beta-2 Gene as a Gene-Editing Strategy for Leukocyte Adhesion Deficiency Type I.
AU - Sevil Raji
AU - Hossein Soltaninejad
AU - Saman Hosseinkhani
AU - Amir Ali Hamidieh
PY - 2026
DA - 2026/10/01
JO - Iranian journal of medical sciences
DO - 10.30476/ijms.2026.109631.4499
UR - https://europepmc.org/article/MED/42999773
AB - Leukocyte adhesion deficiency (LAD) is a genetic immunodeficiency that severely impairs the leukocyte adhesion cascade and migration to the sites of infection and inflammation. As a result, the main consequence is recurrent and severe infections with bacteria and fungi, which can lead to death. The most common variant, LAD-I, is due to mutations in the integrin beta 2 (ITGB2) gene responsible for the β2 integrin (CD18) subunit. Corrective strategies based on gene therapy and genome editing are the most promising methods for treating genetic defects. In the present experimental in vitro study conducted at Tarbiat Modares University, Tehran, Iran, in 2024, we designed a single-guide RNA (sgRNA) for the CRISPR/Cas9 system to target exon 6 of ITGB2 and performed validation experiments. We also investigated peptide nanocarriers as a potential strategy for delivering the CRISPR components. The PX458 plasmid encoding Cas9 and the designed sgRNA was delivered into HEK293T cells, followed by genome-editing analysis. Genome-editing analysis confirmed a measurable level of indel formation at the target locus. Furthermore, the results of MPG nanopeptide production and purification demonstrate the potential of peptide nanocarriers for genome-editing systems. Overall, this work establishes a foundation for subsequent knock-in and gene-correction studies in clinically relevant immune cell models, paving the way for potential LAD-I gene therapy applications.
SN - 0253-0716
SN - 1735-3688
ER -